Drug/Small Molecule:
fluvoxamine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for fluvoxamine and CYP2D6

This label is on the FDA Biomarker List
Informative PGx

Summary

Fluvoxamine appears to inhibit several cytochrome P450 isoenzymes as it exhibits substantial interactions with drugs metabolized by the same isoenzymes. Caution should be used in treating patients with low CYP2D6 activity and those receiving other medication known to inhibit CYP2D6.

Annotation

CYP2C9 and CYP2C19 were previously listed on the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels," but have since been removed (January 2013).

PGx information can be found in the Drug Interactions label section.

Excerpts from the fluvoxamine label:

Based on a finding of substantial interactions of fluvoxamine with certain of these drugs... and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of others drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g.,omeprazole).
In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.

Caution is indicated in patients known to have reduced levels of cytochrome P450 2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the fluvoxamine drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Death
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depression
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depressive Disorder
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Obsessive-Compulsive Disorder
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Schizophrenia
    • Warnings section
    • source: PHONT
  • CYP1A2
    • Drug interactions section, Warnings and precautions section, metabolism/PK
    • source: FDA Label
  • CYP2C19
    • Drug interactions section, metabolism/PK
    • source: FDA Label
  • CYP2C9
    • Drug interactions section, metabolism/PK
    • source: FDA Label
  • CYP2D6
    • Drug interactions section, metabolism/PK
    • source: FDA Label
  • CYP3A4
    • Drug interactions section, Warnings and precautions section, metabolism/PK
    • source: FDA Label

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1B N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2B N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2C N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *8 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *11 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *13 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *15 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *16 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *18 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *19 N/A N/A N/A
VIP CA VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1XN N/A N/A N/A
VIP No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2XN N/A N/A N/A
VIP CA VA CYP2D6 *3 N/A N/A N/A
VIP CA VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA CYP2D6 *5 N/A N/A N/A
VIP CA VA CYP2D6 *6 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *9 N/A N/A N/A
VIP CA VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *14 N/A N/A N/A
VIP No VIP available VA CYP2D6 *17 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *29 N/A N/A N/A
VIP No VIP available VA CYP2D6 *41 N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 L allele-rs25531C N/A N/A N/A
No VIP available No VIP available VA SLC6A4 L allele-rs25531T N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available CA VA
rs10042486 13855688C>T, 1791G>A, 63261329C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1062613 -24T>C, 113846006T>C, 17408422T>C, 210T>C, 5210T>C, HTR3A:C178T, Pro16Ser
T > C
Not Available
VIP No Clinical Annotations available No Variant Annotations available
rs1065852 100C>T, 21917263G>A, 42526694G>A, 5190C>T, CYP2D6:100C>T, Pro34Ser, part of CYP2D6*4 and CYP2D6*10
G > A
Missense
Pro34Ser
No VIP available No Clinical Annotations available VA
rs1160351 280+127738T>G, 29015982A>C, 48015982A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs1176744 113803028A>C, 17365444A>C, 32440A>C, 386A>C, Tyr129Ser
A > C
Missense
Tyr129Ser
No VIP available CA VA
rs1364043 13845210T>G, 63250851T>G
T > G
Not Available
VIP No Clinical Annotations available No Variant Annotations available
rs16947 21914512A>G, 42523943A>G, 733C>C, 7941C>C, 886C>C, Arg245=, Arg296=, CYP2D6:2850C>T
A > G
Not Available
No VIP available CA VA
rs2032583 187004T>C, 25193404A>G, 2685+49T>C, 87160561A>G
A > G
Intronic
No VIP available CA VA
rs2235040 181815G>A, 2481+24G>A, 25198593C>T, 87165750C>T
C > T
Intronic
VIP No Clinical Annotations available No Variant Annotations available
rs28371706 21916341G>A, 320C>T, 42525772G>A, 6112C>T, CYP2D6:1023 C>T, Thr107Ile
G > A
Missense
Thr107Ile
VIP No Clinical Annotations available No Variant Annotations available
rs28371725 21914374C>T, 42523805C>T, 8079G>A, 832+39G>A, 985+39G>A, CYP2D6*41, CYP2D6:2988G>A, part of CYP2D6*41
C > T
Intronic
VIP No Clinical Annotations available No Variant Annotations available
rs35742686 -1793delT, -1830delT, -1940delT, 23418678delT, 40+2664delT, 42128242delT, 50569delT, 50583delT, 598delA, 622delA, 6750delA, 775delA, Arg200Glyfs, Arg208Glyfs, Arg259Glyfs
T > -
Not Available
Arg208Gly
rs3892097 21915516C>T, 353-1G>A, 42524947C>T, 506-1G>A, 6937G>A, CYP2D6*4, CYP2D6:1846G>A, part of CYP2D6*4
C > T
Acceptor
No VIP available CA VA
rs4680 1-5G>A, 19951271G>A, 27009G>A, 3103421G>A, 322G>A, 472G>A, COMP: Val158Met, COMT:Val108Met, Val108Met, Val158Met
G > A
5' Flanking
Val158Met
VIP No Clinical Annotations available No Variant Annotations available
rs5030655 -1098delA, -1563delA, -951delA, -988delA, 23419520delA, 277delT, 353-140delT, 40+3506delA, 42129084delA, 454delT, 51411delA, 51425delA, 5908delT, CYP2D6*6, CYP2D6:1707 del T, Trp152Glyfs, Trp93Glyfs, part of CYP2D6*6
A > -
Not Available
Trp152Gly
VIP No Clinical Annotations available No Variant Annotations available
rs5030656 21914745_21914747delCTT, 42524176_42524178delCTT, 688_690delAAG, 7706_7708delAAG, 841_843delAAG, Lys230del, Lys281del
CTT > -
CTT > TTC
Non-synonymous
No VIP available No Clinical Annotations available VA
rs57098334 GGGTGGGCT, SLC6A4:
C > (CCCACCCGA)9
C > (CCCACCCGA)10
C > (CCCACCCGA)12
Not Available
VIP No Clinical Annotations available No Variant Annotations available
rs59421388 1012G>A, 21914179C>T, 3271G>A, 42523610C>T, 8274G>A, 859G>A, CYP2D6: 3183G>A, Val287Met, Val338Met
G > T
G > C
Missense
Val287Met
VIP No Clinical Annotations available No Variant Annotations available
rs61736512 1747G>A, 21915703C>T, 353-188G>A, 406G>A, 42525134C>T, 6750G>A, CYP2D6: 1659G>A, Val136Met
G > T
G > C
Intronic
Val136Met
No VIP available CA VA
rs6295 1-1019C>G, 1-1019G>C, 13852924C>C, 13852924C>G, 4555G>C, 4555G>G, 63258565C>C, 63258565C>G, HTR1A: -1019C/G
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs6311 -1438, -510G>A, -998G>A, 28451478C>T, 4692G>A, 47471478C>T, G>A, HTR2A c.-1438G>A, HTR2A:, HTR2A: -1438G/A, HTR2A:-1438G>A
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Fluvoxamina [INN-Spanish]
  • Fluvoxamine maleate
  • Fluvoxaminum [INN-Latin]
  • fluvoxamine
  • fluvoxamine-CR
Trade Names
  • Dumirox
  • Dumyrox
  • Faverin
  • Fevarin
  • Floxyfral
  • Luvox
  • Maveral
Brand Mixture Names

PharmGKB Accession Id:
PA449690

Description

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

Source: Drug Bank

Indication

For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT 1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for alpha 1- or alpha 2-adrenergic, beta-adrenergic, muscarinic, dopamine D 2, histamine H 1, GABA-benzodiazepine, opiate, 5-HT 1, or 5-HT 2 receptors.

Source: Drug Bank

Pharmacology

Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT 1A, 5HT 1B, 5HT 2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Avoid high doses of caffeine.|Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

~77-80% (plasma protein)

Source: Drug Bank

Absorption

Well absorbed, bioavailability of fluvoxamine maleate is 53%.

Source: Drug Bank

Half-Life

15.6 hours

Source: Drug Bank

Toxicity

Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.

Source: Drug Bank

Route of Elimination

The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.

Source: Drug Bank

Volume of Distribution

  • 25 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C15H21F3N2O2

Source: Drug Bank

Isomeric SMILES

COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F

Source: Drug Bank

COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F

Source: Drug Bank

Canonical SMILES

COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F

Source: Drug Bank

Average Molecular Weight

318.3346

Source: Drug Bank

Monoisotopic Molecular Weight

318.155512541

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics
    Genes involved in serotonin synthesis, release, reuptake, and in mediation of the antidepressant effect of selective serotonin reuptake inhibitors (SSRI) in human brain.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
HTR1A (source: Drug Bank)
HTR2A (source: Drug Bank)
SLC6A4 (source: Drug Bank)

Drug Interactions

Drug Description
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of theophylline (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of cilostazol (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine The antidepressant increases the effect of clozapine (source: Drug Bank)
fluvoxamine The antidepressant increases the effect of clozapine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
fluvoxamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
fluvoxamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
acenocoumarol Fluvoxamine increases the effect of the anticoagulant (source: Drug Bank)
acenocoumarol Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration. (source: Drug Bank)
almotriptan Increased risk of CNS adverse effects (source: Drug Bank)
almotriptan Increased risk of CNS adverse effects (source: Drug Bank)
aminophylline Increases the effect and toxicity of theophylline (source: Drug Bank)
amitriptyline Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
amitriptyline The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
amoxapine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
amoxapine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
amphetamine Risk of serotoninergic syndrome (source: Drug Bank)
amphetamine Risk of serotoninergic syndrome (source: Drug Bank)
anisindione Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration. (source: Drug Bank)
astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
benzphetamine Risk of serotoninergic syndrome (source: Drug Bank)
benzphetamine Risk of serotoninergic syndrome (source: Drug Bank)
carbamazepine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
cilostazol Fluvoxamine increases the effect of cilostazol (source: Drug Bank)
clomipramine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
clomipramine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
clozapine The antidepressant increases the effect of clozapine (source: Drug Bank)
clozapine The antidepressant increases the effect of clozapine (source: Drug Bank)
desipramine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
desipramine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
dexfenfluramine Risk of serotoninergic syndrome (source: Drug Bank)
dextroamphetamine Risk of serotoninergic syndrome (source: Drug Bank)
dextroamphetamine Risk of serotoninergic syndrome (source: Drug Bank)
dicumarol Fluvoxamine increases the effect of the anticoagulant (source: Drug Bank)
dicumarol Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration. (source: Drug Bank)
diethylpropion Risk of serotoninergic syndrome (source: Drug Bank)
dihydroergotamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
doxepin Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
doxepin The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
duloxetine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
dyphylline Increases the effect and toxicity of theophylline (source: Drug Bank)
eletriptan Increased risk of CNS adverse effects (source: Drug Bank)
eletriptan Increased risk of CNS adverse effects (source: Drug Bank)
ergotamine Possible ergotism and severe ischemia with this combination (source: Drug Bank)
ethotoin Increases the effect of hydantoin (source: Drug Bank)
fenfluramine Risk of serotoninergic syndrome (source: Drug Bank)
fenfluramine Risk of serotoninergic syndrome (source: Drug Bank)
fosphenytoin Increases the effect of hydantoin (source: Drug Bank)
frovatriptan Increased risk of CNS adverse effects (source: Drug Bank)
imipramine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
imipramine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
linezolid Combination associated with possible serotoninergic syndrome (source: Drug Bank)
linezolid Combination associated with possible serotoninergic syndrome (source: Drug Bank)
lithium The SSRI increases serum levels of lithium (source: Drug Bank)
lithium The SSRI, fluvoxamine, increases serum levels of lithium. (source: Drug Bank)
mazindol Risk of serotoninergic syndrome (source: Drug Bank)
mazindol Risk of serotoninergic syndrome (source: Drug Bank)
mephenytoin Increases the effect of hydantoin (source: Drug Bank)
mephenytoin Increases the effect of hydantoin (source: Drug Bank)
mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
methadone Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
methadone Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
methamphetamine Risk of serotoninergic syndrome (source: Drug Bank)
methamphetamine Risk of serotoninergic syndrome (source: Drug Bank)
mexiletine Increases the effect and toxicity of mexiletine (source: Drug Bank)
mexiletine Increases the effect and toxicity of mexiletine (source: Drug Bank)
mirtazapine Increases the effect adn toxicity of mirtazapine (source: Drug Bank)
mirtazapine Increases the effect adn toxicity of mirtazapine (source: Drug Bank)
moclobemide Increased incidence of adverse effects with this association (source: Drug Bank)
moclobemide Increased incidence of adverse effects with this association (source: Drug Bank)
naratriptan Increased risk of CNS adverse effects (source: Drug Bank)
naratriptan Increased risk of CNS adverse effects (source: Drug Bank)
nortriptyline Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
nortriptyline The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
olanzapine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
olanzapine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
oxtriphylline Increases the effect and toxicity of theophylline (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
oxycodone Increased risk of serotonin syndrome (source: Drug Bank)
phendimetrazine Risk of serotoninergic syndrome (source: Drug Bank)
phendimetrazine Risk of serotoninergic syndrome (source: Drug Bank)
phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
phentermine Risk of serotoninergic syndrome (source: Drug Bank)
phenylpropanolamine Risk of serotoninergic syndrome (source: Drug Bank)
phenytoin Increases the effect of hydantoin (source: Drug Bank)
phenytoin Increases the effect of hydantoin (source: Drug Bank)
protriptyline Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
protriptyline The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
ramelteon Fluvoxamine increases the levels/toxicity of ramelteon (source: Drug Bank)
rasagiline Possible severe adverse reaction with this combination (source: Drug Bank)
rizatriptan Increased risk of CNS adverse effects (source: Drug Bank)
rizatriptan Increased risk of CNS adverse effects (source: Drug Bank)
ropinirole Increases the effect and toxicity of ropinirole (source: Drug Bank)
ropivacaine Increases the effect and toxicity of ropivacaine (source: Drug Bank)
ropivacaine Increases the effect and toxicity of ropivacaine (source: Drug Bank)
selegiline Possible severe adverse reaction with this combination (source: Drug Bank)
selegiline Possible severe adverse reaction with this combination (source: Drug Bank)
sibutramine Risk of serotoninergic syndrome (source: Drug Bank)
sibutramine Risk of serotoninergic syndrome (source: Drug Bank)
sumatriptan Increased risk of CNS adverse effects (source: Drug Bank)
sumatriptan Increased risk of CNS adverse effects (source: Drug Bank)
tacrine Fluvoxamine increases the effect of tacrine (source: Drug Bank)
tacrine Fluvoxamine increases the effect of tacrine (source: Drug Bank)
terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
theophylline Increases the effect and toxicity of theophylline (source: Drug Bank)
theophylline Increases the effect and toxicity of theophylline (source: Drug Bank)
thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
tizanidine Fluvoxamine increases the effect/toxicity of tizanidine (source: Drug Bank)
tizanidine Fluvoxamine increases the effect/toxicity of tizanidine (source: Drug Bank)
tramadol Increased risk of serotonin syndrome (source: Drug Bank)
tramadol Increased risk of serotonin syndrome (source: Drug Bank)
tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
trimipramine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
trimipramine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
warfarin Fluvoxamine increases the effect of the anticoagulant (source: Drug Bank)
warfarin Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration. (source: Drug Bank)
zolmitriptan Increased risk of CNS adverse effects (source: Drug Bank)
zolmitriptan Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of hydantoin (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. (source: Drug Bank)
fluvoxamine Combination associated with possible serotoninergic syndrome (source: Drug Bank)
fluvoxamine Combination associated with possible serotoninergic syndrome (source: Drug Bank)
fluvoxamine The SSRI increases serum levels of lithium (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, increases serum levels of lithium. (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of mexiletine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of mexiletine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of mirtazapine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of mirtazapine (source: Drug Bank)
fluvoxamine Increased incidence of adverse effects with this association (source: Drug Bank)
fluvoxamine Increased incidence of adverse effects with this association (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Increased risk of CNS adverse effects (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of tricyclics (source: Drug Bank)
fluvoxamine The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of olanzapine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of theophylline (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Risk of serotoninergic syndrome (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of hydantoin (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of hydantoin (source: Drug Bank)
fluvoxamine Fluvoxamine increases levels/toxicity of ramelteon (source: Drug Bank)
fluvoxamine Fluvoxamine increases levels/toxicity of ramelteon (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Fluvoxamine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Fluvoxamine is initiated, discontinued or if the dose is changed. (source: Drug Bank)
fluvoxamine Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of Tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of Tacrine. (source: Drug Bank)
fluvoxamine Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of theophylline (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of theophylline (source: Drug Bank)
fluvoxamine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluvoxamine The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect/toxicity of tizanidine (source: Drug Bank)
fluvoxamine Fluvoxamine inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated. (source: Drug Bank)
fluvoxamine Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. (source: Drug Bank)
fluvoxamine Tramadol increases the risk of serotonin syndrome and seizures. (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies. (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Fluvoxamine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
fluvoxamine The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy. (source: Drug Bank)
fluvoxamine The strong CYP2C19 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Increased risk of serotonin syndrome. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Fluvoxamine is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
fluvoxamine The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
fluvoxamine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
fluvoxamine Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to fluvoxamine: 75

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in major depression: a comprehensive meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2013. Niitsu Tomihisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. The pharmacogenomics journal. 2013. Brandl E J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. Journal of clinical psychopharmacology. 2013. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry research. 2012. Kurose Kouichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. The pharmacogenomics journal. 2012. de Klerk O L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. European journal of clinical pharmacology. 2012. Azuma Junichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. European journal of clinical pharmacology. 2011. Ishiguro Shin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. Pharmacopsychiatry. 2011. Paulzen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Wang Huijuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Journal of psychopharmacology (Oxford, England). 2011. Suzuki Yutaro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. European psychiatry : the journal of the Association of European Psychiatrists. 2010. Benedetti F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010. Becker Mara L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HTR2A is associated with SSRI response in Major Depressive Disorder in a Japanese cohort. Neuromolecular medicine. 2010. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. Journal of child and adolescent psychopharmacology. 2010. Harris Elana, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. Journal of affective disorders. 2010. Yevtushenko Olga O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics. 2010. Morag Ayelet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (Clinical research ed.). 2010. Kelly Catherine M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biological & pharmaceutical bulletin. 2010. Katoh Yasuhiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. European journal of clinical pharmacology. 2009. Sugahara Hideyo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009. Thomas Kelan L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. Journal of pharmacological sciences. 2009. Vezmar Sandra, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry research. 2009. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2009. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2009. Hori Hikaru, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Therapeutic drug monitoring. 2008. Watanabe Junzo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008. Kronenberg Sefi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?. Neuroscience letters. 2008. Baune B T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. British journal of clinical pharmacology. 2008. Bijl Monique J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Suzuki Yutaro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International clinical psychopharmacology. 2005. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. Journal of clinical psychopharmacology. 2004. Eap Chin B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. European journal of clinical pharmacology. 2004. Kawanishi Chiaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Some aspects of genetic polymorphism in the biotransformation of antidepressants. Thérapie. 2004. Brøsen Kim. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. The pharmacogenomics journal. 2004. Suzuki Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Therapeutic drug monitoring. 2003. Gerstenberg Gisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology. 2003. Gerstenberg Gisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003. Yu Ai-Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. European journal of clinical pharmacology. 2003. Ohara Koichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Takahashi Hitoshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry research. 2002. Ito K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2002. Yoshida Keizo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. The Journal of pharmacology and experimental therapeutics. 2002. Thomas Dierk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug metabolism and drug interactions. 2002. Jan Michael W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Journal of clinical psychopharmacology. 2001. Ozdemir V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. The pharmacogenomics journal. 2002. Di Bella D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The major fluvoxamine metabolite in urine is formed by CYP2D6. European journal of clinical pharmacology. 2001. Spigset O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological psychiatry. 2001. Zanardi R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular psychiatry. 2001. Serretti A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug metabolism and disposition: the biological fate of chemicals. 2000. Hesse L M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Science, medicine, and the future: Pharmacogenetics. BMJ (Clinical research ed.). 2000. Wolf C R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clinical pharmacology and therapeutics. 2000. Härtter S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. European journal of clinical pharmacology. 1999. Hemeryck A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular psychiatry. 1998. Smeraldi E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differences in interactions of SSRIs. International clinical psychopharmacology. 1998. Brøsen K. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Non-linear fluvoxamine disposition. British journal of clinical pharmacology. 1998. Spigset O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European journal of clinical pharmacology. 1997. Spigset O, et al. PubMed
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clinical pharmacology and therapeutics. 1996. Carrillo J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical pharmacokinetics. 1996. Baumann P. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacological research : the official journal of the Italian Pharmacological Society. 1995. Vandel S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. International journal of psychiatry in medicine. 1995. Shen W W. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?. Thérapie. 1992. Bonnet P, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
57664-357-88
DrugBank:
DB00176
ChEBI:
5138
KEGG Compound:
C07571
PubChem Compound:
3404
5324346
PubChem Substance:
46507588
9774
Drugs Product Database (DPD):
2262630
ChemSpider:
3287
Therapeutic Targets Database:
DNC000897
FDA Drug Label at DailyMed:
4fa83401-321d-4fb9-bd7f-8cfa966782e3

Clinical Trials

These are trials that mention fluvoxamine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.